CBLIF and tuberculosis: The risk has been described as being higher with monoclonal antibodies (INF/ADA), as compared with ETN, and times to TB onset from anti-TNFα drug implementation are shorter with INF (median time: 5.5 months) than with ETN (13.4 months) or ADA (18.5 months) [1].